Pacira BioSciences, Inc.
PCRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $1 | $1 | $1 |
| Enterprise Value | $1 | $1 | $2 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -0.9% | 7.2% | -9.8% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 80.9% | 77.4% | 79.7% | 78.7% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 19.1% | 16.1% | 19.9% | 27% |
| Net Income | $0 | -$0 | $0 | $0 |
| % Margin | 3% | -2.7% | 2.8% | 8.6% |
| EPS Diluted | 0.12 | -0.11 | 0.1 | 0.34 |
| % Growth | 209.1% | -210% | -70.6% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |